Toggle Main Menu Toggle Search

Open Access padlockePrints

Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice

Lookup NU author(s): Dr Kathryn White, Professor Rudy Bilous, Emerita Professor Sally Marshall

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

OBJECTIVE: Podocyte-specific, doxycycline (DOX)-inducible overexpression of soluble vascular endothelial growth factor (VEGF) receptor-1 (sFlt-1) in adult mice was used to investigate the role of the VEGF-A/VEGF receptor (VEGFR) system in diabetic glomerulopathy. RESEARCH DESIGN AND METHODS: We studied nondiabetic and diabetic transgenic mice and wild-type controls treated with vehicle (VEH) or DOX for 10 weeks. Glycemia was measured by a glucose-oxidase method and blood pressure by a noninvasive technique. sFlt-1, VEGF-A, VEGFR2, and nephrin protein expression in renal cortex were determined by Western immunoblotting; urine sFlt-1, urine free VEGF-A, and albuminuria by enzyme-linked immunosorbent assay; glomerular ultrastructure by electron microscopy; and VEGFR1 and VEGFR2 cellular localization with Immunogold techniques. RESULTS: Nondiabetic DOX-treated transgenic mice showed a twofold increase in cortex sFlt-1 expression and a fourfold increase in sFlt-1 urine excretion (P < 0.001). Urine free VEGF-A was decreased by 50%, and cortex VEGF-A expression was upregulated by 30% (P < 0.04). VEGFR2 expression was unchanged, whereas its activation was reduced in DOX-treated transgenic mice (P < 0.02). Albuminuria and glomerular morphology were similar among groups. DOX-treated transgenic diabetic mice showed a 60% increase in 24-h urine sFlt-1 excretion and an approximately 70% decrease in urine free VEGF-A compared with VEH-treated diabetic mice (P < 0.04) and had lower urine albumin excretion at 10 weeks than VEH-treated diabetic (d) mice: d-VEH vs. d-DOX, geometric mean (95% CI), 117.5 (69-199) vs. 43 (26.8-69) mug/24 h (P = 0.003). Diabetes-induced mesangial expansion, glomerular basement membrane thickening, podocyte foot-process fusion, and transforming growth factor-beta1 expression were ameliorated in DOX-treated diabetic animals (P < 0.05). Diabetes-induced VEGF-A and nephrin expression were not affected in DOX-treated mice. CONCLUSIONS: Podocyte-specific sFlt-1 overexpression ameliorates diabetic glomerular injury, implicating VEGF-A in the pathogenesis of this complication.


Publication metadata

Author(s): Ku CH, White KE, Dei Cas A, Hayward A, Webster Z, Bilous RW, Marshall SM, Viberti G, Gnudi L

Publication type: Article

Publication status: Published

Journal: Diabetes

Year: 2008

Volume: 57

Issue: 10

Pages: 2824-2833

ISSN (print): 0012-1797

ISSN (electronic): 1939-327X

Publisher: American Diabetes Association

URL: http://dx.doi.org/10.2337/db08-0647

DOI: 10.2337/db08-0647

Notes: Ku, Ching-Hsin White, Kathryn E Dei Cas, Alessandra Hayward, Anthea Webster, Zoe Bilous, Rudy Marshall, Sally Viberti, Giancarlo Gnudi, Luigi S13745/Biotechnology and Biological Sciences Research Council/United Kingdom Research Support, Non-U.S. Gov't United States Diabetes Diabetes. 2008 Oct;57(10):2824-33. Epub 2008 Jul 22.


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
European Foundation
RD04/0002860Diabetes UK
S13745Biotechnology and Biological Sciences Research Council

Share